Charcot–Marie–Tooth Disease and Implications on Corneal Refractive Surgery

Majid Moshirfar · Alyson N. Tukan · Nour Bundogji · Yasmyne C. Ronquillo

Received: March 30, 2022 / Accepted: May 4, 2022 / Published online: June 11, 2022
© The Author(s) 2022

ABSTRACT

Charcot–Marie–Tooth (CMT) disease is the most common inherited polyneuropathy, with a characteristic phenotype of distal muscle weakness, atrophy, and sensory loss. Variable ocular involvement has been documented in patients with CMT, with optic atrophy as the most frequently reported symptom. Although the Charcot–Marie–Tooth Association has generally deemed laser-assisted in situ keratomileuses (LASIK) a safe option for patients with CMT, reports of corneal refractive surgery are lacking in this patient population. This commentary discusses the current understanding of CMT, including its ocular manifestations, and additional specific testing to consider when evaluating these patients for corneal refractive surgery.

Keywords: Charcot–Marie–Tooth disease; LASIK; Optic atrophy; PRK; Polyneuropathy

Key Summary Points

Charcot–Marie–Tooth (CMT) disease is the most common inherited polyneuropathy, with systemic symptoms of distal weakness, muscle atrophy, and sensory loss.

Ocular involvement is less common, though documented symptoms have included optic atrophy, Argyll Robertson-like pupils, fixed miosis, color vision abnormalities, and retinitis pigmentosa, among others.

The Charcot–Marie–Tooth Association states that “patients with CMT are at no additional risk in having laser-assisted in situ keratomileuses (LASIK) or other corrective procedures,” though data is lacking on outcomes of corneal refractive surgery in this patient population.

A LASIK evaluation for a patient with CMT should include corneal confocal microscopy, formal visual field testing, retinal and optic nerve optical coherence tomography (OCT), visual evoked potentials, electroretinograms, and genetic testing.
Because ocular involvement is variable in CMT and the literature is lacking in reports of LASIK in patients with CMT, surgeons should consider a patient’s disease presentation in the context of thorough preoperative testing when counseling patients on the appropriateness of corneal refractive surgery.

INTRODUCTION

As an ophthalmologist, you may encounter a patient with Charcot–Marie–Tooth (CMT) disease seeking corneal refractive surgery. The Charcot–Marie–Tooth Association states that “to our knowledge, people with CMT are at no additional risk in having LASIK or other corrective procedures” [1]. While this statement is encouraging for patients interested in pursuing corneal refractive surgery, it falls short in elucidating specific considerations regarding laser vision correction in CMT. We would like to share our perspective on corneal refractive surgery in patients with CMT given the disease pathophysiology and ophthalmic manifestations. We also explore additional specific testing to consider in the preoperative evaluation for potential laser-assisted in situ keratomileusis (LASIK) or other corneal refractive surgery in patients with CMT.

Interestingly, CMT is named after the three neurologists who described the disease in 1886 [2]. Jean-Martin Charcot, an anatomy professor and the “father of neurology” [3], alongside his student Pierre Marie [4], published reports in Paris while Howard Henry Tooth documented similar cases for his doctoral thesis at the University of Cambridge [5]. Also known as hereditary motor and sensory neuropathy (HMSN), CMT is the most common inherited polyneuropathy with an estimated prevalence of 1 in 2500 [6]. CMT is caused by multiple mutations in structural protein genes responsible for myelin sheath and Schwann cell formation, mitochondrial metabolism, and axonal transport, resulting in length-dependent neuropathy. The distal nerves are affected first, followed by progressive proximal involvement [7]; thus, the classic presentation of CMT includes distal muscle weakness and atrophy. Other less common findings can include scoliosis, hip dysplasia, restless leg syndrome, tremor, and hearing loss [6]. Disease onset is usually in the first [6] or second [8] decade of life, though presentation and severity of symptoms can differ depending on the underlying gene mutation.

According to conduction velocity abnormalities, CMT is classified as axonal, demyelinating, or intermediate (Table 1) [6]. As a result of genetic heterogeneity, disease presentation can be highly variable and difficult to diagnose. The diagnosis involves clinical assessment, review of family history, nerve conduction velocity studies, electromyogram, and genetic testing [7]. Currently, there are no pharmacological treatments for CMT. Management instead revolves around supportive therapies, such as physical therapy and orthopedic devices [7]. Some investigational therapies, such as progesterone antagonists, neurotrophic growth factor, ascorbic acid, and curcumin, have not yet revealed definitive results [8].

Although less common than symptoms of peripheral neuropathy, ocular involvement has been documented. There are reports of Argyll Robertson-like pupils [9] and fixed miosis secondary to involvement of sympathetic postganglionic fibers [10]. Oculomotor abnormalities due to cranial nerve involvement have also been documented [10]. Optic atrophy has been observed in the CMT2A variant, secondary to mitofusin-2 MFN2 gene abnormalities [11, 12]. Other ocular manifestations of CMT include red/green color vision abnormalities, premature presbyopia, nystagmus, retinitis pigmentosa, peripapillary vessel attenuation, retinal nerve fiber layer thinning, and central/paracentral scotoma [13]. Table 2 outlines the abnormalities described above.

Dry eye disease is not a well-documented ocular manifestation of CMT, though it is a possible symptom given that CMT affects nerves throughout the body and the cornea is one of the most densely innervated tissues [14]. This relationship becomes significant when
Table 1 Overview of CMT subtypes and associated characteristics

| Subtype | Inheritance pattern* | Pathophysiology | Phenotype |
|---------|----------------------|-----------------|-----------|
| CMT1    | AD                   | Demyelinating disease → slowed nerve conduction velocity [7] | Muscle weakness, peripheral atrophy [2]. Severity of symptoms does not correlate with degree of reduction in nerve conduction velocity [23] |
| CMT1A** | AD                   | Duplication of peripheral myelin protein 22 kD (PMP22) gene [6, 7] | Symptom onset in infancy; distal weakness, atrophy, high stepping gait, decreased sensation, pes cavus, reduced/absent reflexes [6, 8] |
| CMT2    | AD                   | Axonal abnormalities → reduced amplitude but normal velocity of nerve conduction [7] | Onset age 5–25 years, distal weakness, atrophy, sensory loss, decreased reflexes, foot deformities [2]; optic atrophy [6]; tremors, migraines [23] |
| CMT3*** | AD or AR             | Abnormalities in genes PMP22, MPZ, GJB, among others → slowed nerve conduction [2] | Onset in infancy, hypotonia, delayed motor development, sensory loss, distal to proximal weakness, absent reflexes, ataxia [2] |
| CMT4    | AR                   | Demyelinating disease → slowed conduction velocity [7] | Distal weakness, atrophy, sensory loss, foot deformities, cataracts, deafness [2]; severe early onset sensory motor neuropathy, vocal cord paresis [23] |
| CMTX    | X-linked             | Most commonly due to mutation in gene GJB1 (codes for gap junction connexin-32) [7, 23] | Distal weakness, atrophy, sensory loss [2]; Primarily affects males, females with later onset (age 20–30 years) and less severe disease [7, 23] |
| Intermediate | AD or AR | Unclear if primarily axonal/ demyelinating → intermediate conduction velocity [7] | Similar symptoms of distal weakness, atrophy, and sensory loss; grouped with traditional subtypes when possible [2] |

CMT5 and CMT6 are now attributed to MFN2 gene abnormalities and grouped with CMT2A [7]
CMT Charcot–Marie–Tooth disease, AD autosomal dominant, AR autosomal recessive
*CMT can also be acquired through de novo mutations [7]
**Most common subtype of CMT
***CMT3 is more commonly known as severe, early-onset CMT, Dejerine–Sottas disease, and congenital hypomyelinating neuropathy [2]

considering corneal refractive surgery, especially LASIK, in patients with CMT. Post-LASIK dry eye disease is postulated to occur as a result of corneal nerve damage in the process of LASIK flap creation, with subsequent tear film dysfunction causing chronic dryness [15]. A prospective study found an inverse relationship between post-LASIK reinnervation and dry eye symptoms, thus supporting that LASIK-associated dry eye disease is a neuropathic process [15]. We are concerned that the underlying pathophysiology of LASIK-associated dry eye disease could be exacerbated in patients with CMT, and surgeons should be cautious about proceeding with corneal refractive surgery in this population.

To further explore the option of LASIK in a patient with CMT, additional testing beyond the standard LASIK evaluation is warranted to better understand the extent of ocular
involvement and potential for a successful corneal refractive surgical outcome (Table 3). One of the most important evaluations is corneal confocal microscopy (CCM), a non-invasive tool that allows direct visualization of the corneal nerves. Specifically, CCM allows for characterization of the sub-basal nerve bundles, which are typically unmyelinated C fibers that sense thermal and chemical stimuli [16]. A patient with CMT may demonstrate decreased nerve fiber density on CCM [16, 17]. Additionally, corneal sensation is reduced with testing such as the non-contact corneal aesthesiometer (NCCA). Taken together, the CCM and NCCA findings demonstrate the corneal nerve integrity of a patient with CMT. Those with severely diminished nerve density and sensation are at risk for more postoperative complications such as dryness and poor postsurgical healing.

In addition to confocal microscopy, other testing can help characterize the extent of ocular CMT. Formal visual field testing can identify any pre-existing deficits secondary to optic atrophy. Central/paracentral scotomas are the most common visual field abnormality in CMT [13]. Furthermore, retinal and optic nerve optical coherence tomography (OCT) are critical to evaluate the integrity of these structures. If a
patient has significant retinal nerve fiber layer
or optic nerve thinning causing impaired
vision, their visual potential is compromised
and they are unlikely to experience significant
improvement in best corrected visual acuity
from corneal refractive surgery. These patients
should be counseled that their structural limi-
tations prevent optimal surgical outcomes and
thus are not good candidates for corneal
refractive surgery. Visual evoked potentials
(VEP) and electroretinograms (ERG) can be
performed as part of a thorough evaluation.
Although they may be normal in some patients,
increased latency or decreased amplitude has
been observed on VEP [18, 19]. Lastly, the
patient should be referred for genetic testing if
they have not yet undergone molecular analy-
sis. Identifying the gene abnormality and inheri-
tance pattern of CMT can help charac-
terize the expected disease progression and
severity.

Since the literature lacks reports of corneal
refractive surgery in patients with CMT, it is
difficult to assess outcomes such as postsurgical
healing. Therefore, it is helpful to investigate
LASIK outcomes in other diseases with corneal
neuropathy, such as diabetes. Both CMT and
diabetes demonstrate decreased corneal sub-
basal nerve density [20]. In diabetes, chronic
hyperglycemia results in axonal degeneration of
unmyelinated corneal nerves, producing symp-
toms of corneal desensitization, decreased cel-
ular regeneration, and slow wound healing
[21]. Although diabetes is generally considered a
relative contraindication to LASIK, a literature
review revealed that patients with good gly-
cemic control generally had favorable postsur-
gical outcomes [21]. Patients with poorer gly-
cemic control were more likely to experience
delayed wound healing, punctate epithelial
erosions, and persistent epithelial defects [22].
By extension, we infer that patients with severe
corneal neuropathy secondary to CMT can have
similar complications associated with poor cor-
neal healing, whereas patients with minimal
corneal manifestations of CMT might be can-
didates for corneal refractive surgery.

In summary, CMT presents a broad spectrum
of disease severities and variable ocular
involvement. Although

The Charcot–Marie–Tooth Association has generally
deeded LASIK a safe option for patients with
CMT, our understanding of the current litera-
ture has identified numerous ophthalmic man-
ifestations that can impact whether a patient is
a good candidate for corneal refractive surgery.
A surgeon should consider a patient’s disease
presentation in the context of thorough pre-
operative testing when counseling patients on
the appropriateness of corneal refractive surgery.

ACKNOWLEDGEMENTS

Funding. This study was funded by an
unrestricted grant from Research to Prevent
Blindness (RPB), 360 Lexington Avenue, 22nd
Floor New York, NY 10017, USA. No support
was received for the publication of this article.

Medical Writing and Editorial Assis-
tance. Special thanks to Yasmyne Ronquillo for
her assistance in editing.

Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work, and have given final approval to
the version to be published.

Author Contributions. Majid Moshirfar MD
contributed to the perspective conception. The
first draft of the manuscript was written by
Alyson Tukan and Nour Bundogji. All authors
contributed to revisions.

Disclosures. All authors declare that they
have no conflict of interest.

Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
**Data Availability.** Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).

**REFERENCES**

1. Medications/Vaccination—Charcot–Marie–Tooth Association. [https://www.cmtausa.org/living-with-cmt/find-help/ask-the-expert/medications-vaccination/](https://www.cmtausa.org/living-with-cmt/find-help/ask-the-expert/medications-vaccination/). Accessed 31 Jan 2022.

2. Charcot–Marie–Tooth Disease (CMT)—Diseases|Muscular Dystrophy Association. [https://www.mda.org/disease/Charcot–Marie–Tooth.](https://www.mda.org/disease/Charcot–Marie–Tooth.) Accessed 27 Mar 2022.

3. Kumar DR, Aslinia F, Yale SH, Mazza JJ. Jean-Martin Charcot: the father of neurology. Clin Med Res. 2011;9(1):46. [https://doi.org/10.3121/CMR.2009.883.](https://doi.org/10.3121/CMR.2009.883.)

4. Pearce JMS. A note on Pierre Marie (1853–1940). J Neurol Neurosurg Psychiatry. 2004;75(11):1583. [https://doi.org/10.1136/jnnp.2003.024729.](https://doi.org/10.1136/jnnp.2003.024729.)

5. Pearce JMS, Howard Henry Tooth (1856–1925). J Neurol. 2000;247(1):3–4. [https://doi.org/10.1007/s004150050002.](https://doi.org/10.1007/s004150050002.)

6. Morena J, Gupta A, Hoyle JC. Charcot–Marie–Tooth: from molecules to therapy. Int J Mol Sci. 2019. [https://doi.org/10.3390/ IJMS20143419.](https://doi.org/10.3390/ IJMS20143419.)

7. Charcot–Marie–Tooth Disease—NORD (National Organization for Rare Disorders). [https://rarediseases.org/rare-diseases/Charcot–Marie–Tooth-disease/.](https://rarediseases.org/rare-diseases/Charcot–Marie–Tooth-disease/) Accessed 31 Jan 2022.

8. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot–Marie–Tooth disease. Lancet Neurol. 2009;8(7):654–67. [https://doi.org/10.1016/S1474-4422(09)70110-3.](https://doi.org/10.1016/S1474-4422(09)70110-3.)

9. Salisachs P, Lapresle J. Argyll-Robertson-like pupils in the neural type of Charcot–Marie–Tooth disease. Eur Neurol. 1977;16(1–6):172–5. [https://doi.org/10.1159/000114897.](https://doi.org/10.1159/000114897.)

10. Oporto JJ, Velasco R, Mori A, Olivares C. Ocular manifestations of Charcot–Marie–Tooth disease: a short review. Int J Ophthalmol Vis Res. 2019;3(1):016–8.

11. Nan H, Hata T, Fukao T, et al. MFN2-related Charcot–Marie–Tooth disease with atypical ocular manifestations. Intern Med. 2021;60(24):3969–74. [https://doi.org/10.2169/internalmedicine.7463-21.](https://doi.org/10.2169/internalmedicine.7463-21.)

12. Hamedani AG, Wilson JA, Avery RA, Scherer SS. Optic neuropathy in Charcot–Marie–Tooth disease. J Neuroophthalmol. 2021;41(2):233–8. [https://doi.org/10.1097/WNO.0000000000000965.](https://doi.org/10.1097/WNO.0000000000000965.)

13. Zayit-Soudry S, Mimouni M. Charcot–Marie–Tooth disease, retinal degeneration. Encycl Ophthalmol. 2018. [https://doi.org/10.1007/978-3-540-69000-9_1013.](https://doi.org/10.1007/978-3-540-69000-9_1013.)

14. Yang AY, Chow J, Liu J. Corneal innervation and sensation: the eye and beyond. Yale J Biol Med. 2018;91(1):13–21.

15. Chao C, Stapleton F, Zhou X, Chen S, Zhou S, Golebiowski B. Structural and functional changes in corneal innervation after laser in situ keratomileusis and their relationship with dry eye. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):2029–39. [https://doi.org/10.1007/S00417-015-3120-1.](https://doi.org/10.1007/S00417-015-3120-1.)

16. Tavakoli M, Marshall A, Banka S, et al. Corneal confocal microscopy detects small-fiber neuropathy in Charcot–Marie–Tooth disease type 1A patients. Muscle Nerve. 2012;46(5):698–704. [https://doi.org/10.1002/MUS.23377.](https://doi.org/10.1002/MUS.23377.)

17. Bitirgen G, Turkmen K, Malik RA, Ozkagnici A, Zengin N. Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease. Sci Rep. 2018. [https://doi.org/10.1038/S41598-018-30688-Z.](https://doi.org/10.1038/S41598-018-30688-Z.)
18. Carroll WM, Jones SJ, Halliday AM. Visual evoked potential abnormalities in Charcot–Marie–Tooth disease and comparison with Friedreich’s ataxia. J Neurol Sci. 1983;61(1):123–33. https://doi.org/10.1016/0022-510X(83)90059-X.

19. Bird TD, Griep E. Pattern reversal visual evoked potentials. Studies in Charcot–Marie–Tooth hereditary neuropathy. Arch Neurol. 1981;38(12):739–41. https://doi.org/10.1001/ARCHNEUR.1981.00510120039003.

20. Wang EF, Misra SL, Patel DV. In vivo confocal microscopy of the human cornea in the assessment of peripheral neuropathy and systemic diseases. Biomed Res Int. 2015. https://doi.org/10.1155/2015/951081.

21. Simpson RG, Moshirfar M, Edmonds JN, Christiansen SM. Laser in-situ keratomileusis in patients with diabetes mellitus: a review of the literature. Clin Ophthalmol. 2012;6(1):1665–74. https://doi.org/10.2147/OPTH.S36382.

22. Fraunfelder FW, Rich LF. Laser-assisted in situ keratomileusis complications in diabetes mellitus. Cornea. 2002;21(3):246–8. https://doi.org/10.1097/00003226-200204000-00002.

23. Casasnovas C, Cano LM, Alberti A, Cespedes M, Rigo G. Charcot–Marie–Tooth disease. Foot Ankle Spec. 2008;1(6):350–4. https://doi.org/10.1177/193864008326247.

24. Spector RH, Smith JL, Chavis PS. Charcot–Marie–Tooth disease mimicking ocular myasthenia gravis. Ann Ophthalmol. 1978;10(8):1033–6.